Miniatura

Fitxers

664932.pdf (530.64 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2015-02-26

Llicència de publicació

cc-by (c) Salazar Soler, Ramón et al., 2015
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/108174

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s12885-015-1053-z

Resum

Background: perioperatory chemoradiotherapy (CRT) improves local control and survival in patients with locally advanced rectal cancer (LARC). The objective of the current study was to evaluate the addition of bevacizumab (BEV) to preoperative capecitabine (CAP)-based CRT in LARC, and to explore biomarkers for downstaging. Methods: patients (pts) were randomized to receive 5 weeks of radiotherapy 45 Gy/25 fractions with concurrent CAP 825 mg/m2 twice daily 5 days per week and BEV 5 mg/kg once every 2 weeks (3 doses) (arm A), or the same schedule without BEV (arm B). The primary end point was pathologic complete response (ypCR: ypT0N0). Results: ninety pts were included in arm A (44) or arm B (46). Grade 3-4 treatment-related toxicity rates were 16% and 13%, respectively. All patients but one (arm A) proceeded to surgery. The ypCR rate was 16% in arm A and 11% in arm B (p =0.54). Fifty-nine percent vs 39% of pts achieved T-downstaging (arm A vs arm B; p =0.04). Serial samples for biomarker analyses were obtained for 50 out of 90 randomized pts (arm A/B: 22/28). Plasma angiopoietin-2 (Ang-2) levels decreased in arm A and increased in arm B (p <0.05 at all time points). Decrease in Ang-2 levels from baseline to day 57 was significantly associated with tumor downstaging (p =0.02). Conclusions: the addition of BEV to CAP-based preoperative CRT has shown to be feasible in LARC. The association between decreasing Ang-2 levels and tumor downstaging should be further validated in customized studies.

Matèries

Anticossos monoclonals, Quimioteràpia del càncer, Càncer colorectal, Malalts de càncer

Matèries (anglès)

Monoclonal antibodies, Cancer chemotherapy, Colorectal cancer, Cancer patients

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SALAZAR SOLER, Ramón, CAPDEVILA, Jaume, LAQUENTE, Berta, MANZANO, José luis, PERICAY, Carles, MARTÍNEZ VILLACAMPA, Mercedes, LÓPEZ LÓPEZ, Carlos, LOSA GASPÀ, Ferran, SAFONT, María josé, GÓMEZ, Auxiliadora, ALONSO, Vicente, ESCUDERO, Pilar, GALLEGO, Javier, SASTRE, Javier, GRÁVALOS, Cristina, BIONDO, Sebastián, PALACIOS, Amalia, ARANDA, Enrique. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. _BMC Cancer_. 2015. Vol. 15, núm. 60. [consulta: 25 de febrer de 2026]. ISSN: 1471-2407. [Disponible a: https://hdl.handle.net/2445/108174]

Exportar metadades

JSON - METS

Compartir registre